AEON Biopharma, Inc.
corporate_fare Company Profile
AEON Biopharma, Inc. (NYSE:AEON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for AEON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for AEON spans 10-Q, 8-K, SCHEDULE 13D/A, 424B3.
Recent high-impact activity:
- AEON 10-Q: $2.5M Q3 Profit Is Non-Cash; Going Concern and $0.25 Delisting Rule Loom
- AEON Posts Q3 Net Income of $2.5M on Warrant Remeasurement; Cash Runway to Q2 2027
- Daewoong Exercises Pre-Funded Warrants, Stake Rises to 30.6% of AEON
- AEON Cuts Two-Year Warrant Strike to $0.20, Expects $6.2M From Exercises Before Nov 16 Expiry
- AEON Cuts Warrant Strike to $0.20, Expects ~$6.2M From Induced Exercises
Financial Snapshot
Short Interest & Short Volume
6.40 days to coverFINRA reported short interest of 2,661,529 shares in AEON as of the October 30, 2026 settlement, a 18.1% decrease from the prior period — about 6.4 days to cover at its recent average daily volume. On November 20, 2026, 59.1% of AEON volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AEON, detected from its recent SEC filings · based on capital-structure filings through 2026-11-03.
Warrant Strike Cut to $0.20 · About $6.2M Expected From Exercises
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →